




PHARMACEUTICAL 2023

Cogent Biosciences Inc.
Rank 126 of 446





RealRate

PHARMACEUTICAL 2023

Cogent Biosciences Inc.
Rank 126 of 446



The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Cogent Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 130% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	264,966
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,849
Liabilities, Non-Current	18,226
Other Assets	28,061
Other Compr. Net Income	-104
Other Expenses	0
Other Liabilities	0
Other Net Income	7,598
Other Revenues	0
Property and Equipment	7,783
Research and Development	121,627
Selling, General and Administrative Expense	26,212

Output Variable	Value in 1000 USD
Assets	300,810
Liabilities	45,075
Expenses	147,839
Revenues	0
Stockholders Equity	255,735
Net Income	-140,241
Comprehensive Net Income	-140,293
Economic Capital Ratio	173%